NPI: 1184012569 · PHILADELPHIA, PA 19104 · Clinical Medical Laboratory · NPI assigned 01/07/2015
Authorized official JACKSON, CHANTE controls 20+ related entities in our dataset. Read more
| Authorized Official | JACKSON, CHANTE (ENROLLMENT LEAD) |
| NPI Enumeration Date | 01/07/2015 |
Other providers sharing the same authorized official: JACKSON, CHANTE
| Year | Claims | Total Paid |
|---|---|---|
| 2020 | 4,272 | $80K |
| 2021 | 24,822 | $434K |
| 2022 | 25,681 | $304K |
| 2023 | 22,157 | $240K |
| 2024 | 23,200 | $270K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 80050 | General health panel | 6,169 | 5,911 | $197K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2,706 | 2,605 | $166K |
| 80061 | Lipid panel | 9,598 | 9,271 | $93K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 3,119 | 3,016 | $66K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 3,303 | 3,130 | $57K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 108 | 106 | $45K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3,377 | 3,194 | $44K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 2,012 | 1,921 | $35K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 1,116 | 1,082 | $34K |
| 83036 | Hemoglobin; glycosylated (A1C) | 8,308 | 7,933 | $33K |
| 80048 | Basic metabolic panel (calcium, ionized) | 4,409 | 4,196 | $32K |
| 80053 | Comprehensive metabolic panel | 3,408 | 3,262 | $30K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2,705 | 2,535 | $29K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 782 | 756 | $29K |
| 84443 | Thyroid stimulating hormone (TSH) | 1,821 | 1,745 | $28K |
| 88237 | 134 | 127 | $25K | |
| 86803 | 1,738 | 1,688 | $25K | |
| 82607 | 3,375 | 3,228 | $24K | |
| 87631 | 177 | 171 | $23K | |
| 85027 | 5,176 | 4,915 | $22K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 385 | 354 | $22K |
| 84153 | 844 | 810 | $20K | |
| 84466 | 1,918 | 1,850 | $20K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 2,483 | 2,347 | $17K |
| 82728 | 2,242 | 2,162 | $17K | |
| 86480 | 272 | 263 | $16K | |
| 82043 | 2,785 | 2,689 | $16K | |
| 82570 | 2,949 | 2,811 | $14K | |
| 87536 | 130 | 123 | $14K | |
| 82746 | 2,532 | 2,405 | $13K | |
| 87088 | 1,901 | 1,804 | $13K | |
| 83540 | 1,951 | 1,882 | $10K | |
| 86592 | 2,370 | 2,297 | $8K | |
| 84439 | 1,644 | 1,569 | $7K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2,100 | 2,012 | $7K |
| 86360 | 109 | 106 | $6K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 40 | 40 | $6K |
| 83735 | 1,021 | 953 | $5K | |
| 86359 | 109 | 106 | $5K | |
| 86706 | 504 | 482 | $4K | |
| 81001 | 2,496 | 2,345 | $4K | |
| 88264 | 31 | 27 | $4K | |
| 88291 | 136 | 121 | $4K | |
| 87077 | 616 | 570 | $4K | |
| 87481 | 92 | 89 | $4K | |
| 87340 | 322 | 316 | $3K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 30 | 25 | $3K |
| 80364 | 94 | 84 | $2K | |
| 87186 | 352 | 327 | $2K | |
| 81003 | 1,421 | 1,352 | $2K | |
| 81513 | 104 | 98 | $2K | |
| 80076 | 370 | 347 | $2K | |
| 85610 | 553 | 460 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 27 | 27 | $2K |
| 87467 | 286 | 274 | $2K | |
| 87081 | 279 | 271 | $2K | |
| 88141 | 170 | 164 | $2K | |
| 85652 | 486 | 465 | $1K | |
| 86038 | 108 | 105 | $1K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 15 | 15 | $896.66 |
| 84403 | 12 | 12 | $370.68 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 16 | 15 | $359.31 |
| 83721 | 53 | 51 | $333.84 | |
| 84481 | 13 | 13 | $102.83 | |
| 83690 | 15 | 12 | $59.00 | |
| 81015 | 25 | 25 | $55.96 | |
| 87070 | 15 | 15 | $55.76 | |
| 87205 | 16 | 16 | $37.22 | |
| 84550 | 13 | 13 | $31.60 | |
| 85007 | 25 | 24 | $26.87 | |
| 85045 | 15 | 13 | $22.98 | |
| 86140 | 13 | 13 | $14.58 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 83 | 83 | $0.00 |